Nature Communications (Aug 2018)
JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML
Abstract
Histone demethylase JMJD3 is known to be oncogenic in preleukemic states and T-cell acute lymphocytic leukemia. Here, the authors show that in some acute myeloid leukemia subsets, JMJD3 can actually act as a potential oncorepressor via mediation of C/EBPβ-centered transcriptional programming.